Body surface potential mapping to monitor the effects of thrombolytic therapy following acute myocardial infarction.
The authors demonstrate the value of body surface potential mapping (BSPM) and a limited lead system in monitoring complete ECG evolution following myocardial infarction (MI) and the effects of thrombolytic therapy. They produced ST-segment isopotential maps, which indicate the site and extent of myocardial injury. Pathological Q wave maps were also produced, which intimate the extent of myocardial necrosis. Analysis of a sequence of maps recorded during the acute phase of MI revealed sudden changes attributed to reperfusion, reinfarction or "silent" events.
Edwards
S W
SW
Department of Computing, Imperial College of Science, Technology and Medicine, London, England.
Monro
D M
DM
Jones
R W
RW
Kidner
P H
PH
D000328:Adult; D000368:Aged; D016255:Anistreplase; D004796:Clinical Enzyme Tests; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography / Q000379:methods; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D010958:Plasminogen / Q000627:therapeutic use; D011877:Radionuclide Imaging; D012815:Signal Processing, Computer-Assisted; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D003402:Creatine Kinase; D013300:Streptokinase